155 related articles for article (PubMed ID: 1333351)
21. Safety of pamidronate in patients with renal failure and hypercalcemia.
Machado CE; Flombaum CD
Clin Nephrol; 1996 Mar; 45(3):175-9. PubMed ID: 8706358
[TBL] [Abstract][Full Text] [Related]
22. Circulating PTH and PTHrP levels before and after treatment of tumor induced hypercalcemia with Pamidronate Disodium (APD).
Grill V; Murray RM; Ho PW; Santamaria JD; Pitt P; Potts C; Jerums G; Martin TJ
J Clin Endocrinol Metab; 1992 Jun; 74(6):1468-70. PubMed ID: 1592895
[TBL] [Abstract][Full Text] [Related]
23. Use of pamidronate in the management of acute cancer-related hypercalcemia in children.
Young G; Shende A
Med Pediatr Oncol; 1998 Feb; 30(2):117-21. PubMed ID: 9403021
[TBL] [Abstract][Full Text] [Related]
24. Randomized, double-blind, phase II trial of gallium nitrate compared with pamidronate for acute control of cancer-related hypercalcemia.
Cvitkovic F; Armand JP; Tubiana-Hulin M; Rossi JF; Warrell RP
Cancer J; 2006; 12(1):47-53. PubMed ID: 16613662
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of new bone resorption markers in a randomized comparison of pamidronate or clodronate for hypercalcemia of malignancy.
Vinholes J; Guo CY; Purohit OP; Eastell R; Coleman RE
J Clin Oncol; 1997 Jan; 15(1):131-8. PubMed ID: 8996134
[TBL] [Abstract][Full Text] [Related]
26. An audit of the management of malignant hypercalcaemia.
Gerrard GE; Dodwell DJ; Vail A; Watters J; Overend MA
Clin Oncol (R Coll Radiol); 1996; 8(1):39-42. PubMed ID: 8688360
[TBL] [Abstract][Full Text] [Related]
27. The effect of age on the renal response to PTH infusion.
Naafs MA; Fischer HR; Koorevaar G; Hackeng WH; Schopman W; Silberbusch J
Calcif Tissue Int; 1987 Nov; 41(5):262-6. PubMed ID: 2825933
[TBL] [Abstract][Full Text] [Related]
28. Serum parathyroid hormone-related protein levels and response to bisphosphonate treatment in hypercalcemia of malignancy.
Rizzoli R; Thiébaud D; Bundred N; Pecherstorfer M; Herrmann Z; Huss HJ; Rückert F; Manegold C; Tubiana-Hulin M; Steinhauer EU; Degardin M; Thürlimann B; Clemens MR; Eghbali H; Body JJ
J Clin Endocrinol Metab; 1999 Oct; 84(10):3545-50. PubMed ID: 10522993
[TBL] [Abstract][Full Text] [Related]
29. Parathyroid hormone-related protein(50-69) and response to pamidronate therapy for tumour-induced hypercalcaemia.
Dodwell DJ; Abbas SK; Morton AR; Howell A
Eur J Cancer; 1991; 27(12):1629-33. PubMed ID: 1782072
[TBL] [Abstract][Full Text] [Related]
30. Effects of treatment of malignancy-associated hypercalcemia on serum parathyroid hormone-related protein.
Budayr AA; Zysset E; Jenzer A; Thiébaud D; Ammann P; Rizzoli R; Jaquet-Müller F; Bonjour JP; Gertz B; Burckhardt P
J Bone Miner Res; 1994 Apr; 9(4):521-6. PubMed ID: 8030440
[TBL] [Abstract][Full Text] [Related]
31. Comparison of different dose regimes of aminohydroxypropylidene-1,1-bisphosphonate (APD) in hypercalcaemia of malignancy.
Davis JR; Heath DA
Br J Clin Pharmacol; 1989 Sep; 28(3):269-74. PubMed ID: 2789920
[TBL] [Abstract][Full Text] [Related]
32. Biochemical effects from treatment with bisphosphonate and surgery in patients with primary hyperparathyroidism.
Jansson S; Morgan E
World J Surg; 2004 Dec; 28(12):1293-7. PubMed ID: 15517486
[TBL] [Abstract][Full Text] [Related]
33. Oral versus intravenous AHPrBP (APD) in the treatment of hypercalcemia of malignancy.
Thiébaud D; Portmann L; Jaeger P; Jacquet AF; Burckhardt P
Bone; 1986; 7(4):247-53. PubMed ID: 3768203
[TBL] [Abstract][Full Text] [Related]
34. Hypercalcemia and childhood cancer: a 7-year experience.
Kerdudo C; Aerts I; Fattet S; Chevret L; Pacquement H; Doz F; Michon J; Garabedian M; Orbach D
J Pediatr Hematol Oncol; 2005 Jan; 27(1):23-7. PubMed ID: 15654274
[TBL] [Abstract][Full Text] [Related]
35. Acute oral calcium load decreases parathyroid secretion and suppresses tubular phosphate loss in long-term renal transplant recipients.
Dumoulin G; Hory B; Nguyen NU; Henriet MT; Bresson C; Regnard J; Saint-Hillier Y
Am J Nephrol; 1995; 15(3):238-44. PubMed ID: 7618649
[TBL] [Abstract][Full Text] [Related]
36. Biochemical changes before and during oral calcium tolerance test in calcium stone formers.
Kitamura T; Hirano Y; Ueda D; Aso Y
Urol Res; 1988; 16(3):149-55. PubMed ID: 2842910
[TBL] [Abstract][Full Text] [Related]
37. [Disodium pamidronate (APD) in therapy of hypercalcemia in primary hyperparathyroidism].
Kotzmann H; Svoboda T; Bernecker P; Clodi M; Woloszczuk W; Niederle B; Waldhäusl W; Luger A
Wien Klin Wochenschr; 1994; 106(13):422-5. PubMed ID: 8091766
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate.
Pecherstorfer M; Steinhauer EU; Rizzoli R; Wetterwald M; Bergström B
Support Care Cancer; 2003 Aug; 11(8):539-47. PubMed ID: 12783289
[TBL] [Abstract][Full Text] [Related]
39. Familial hypocalciuric hypercalcaemia: observations on vitamin D metabolism and parathyroid function.
Davies M; Adams PH; Berry JL; Lumb GA; Klimiuk PS; Mawer EB; Wain D
Acta Endocrinol (Copenh); 1983 Oct; 104(2):210-5. PubMed ID: 6314724
[TBL] [Abstract][Full Text] [Related]
40. Hypercalcemia in patients with disseminated coccidioidomycosis.
Caldwell JW; Arsura EL; Kilgore WB; Reddy CM; Johnson RH
Am J Med Sci; 2004 Jan; 327(1):15-8. PubMed ID: 14722391
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]